Potential of free-form TFPI and PAI-1 to be useful markers of early atherosclerosis in a Japanese general population (the Suita Study): Association with the intimal-medial thickness of carotid arteries

Atherosclerosis

Volumn 176, Issue 2, 2004, Pages 355-360

  Sakata, Toshiyuki ^a   Mannami, Toshifumi ^a   Baba, Shunroku ^a   Kokubo, Yoshihiro ^a   Kario, Kazuomi ^b   Okamoto, Akira ^a   Kumeda, Kousuke ^c   Ohkura, Naoki ^a   Katayama, Yoshiaki ^a   Miyata, Toshiyuki ^a   Tomoike, Hitonobu ^a   Kato, Hisao ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Atherosclerosis; Endothelium derived factors; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE FACTOR PATHWAY INHIBITOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES MELLITUS; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; HUMAN; HYPERLIPIDEMIA; INTIMA; JAPAN; LIFESTYLE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; THICKNESS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CAROTID ARTERY DISEASES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; REFERENCE VALUES; SERINE PROTEINASE INHIBITORS; TUNICA INTIMA;

EID: 5644248267     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2004.05.017     Document Type: Article

References (30)

1. Hodis H.N., Mack W.J. Risk factor assessment, treatment strategy and prevention of coronary artery disease: the need for a more rational approach. J Intern Med. 236:1994;111-113
2. Blankenhorn D.H., Hodis H.N. Arteial imaging and atherosclerosis reversal. Arterioscler Thromb. 14:1994;177-192
3. Geroulakos G., O'Gorman D.J., Kalodiki E., Sheridan G.J., Nicolaides A.N. The carotid intima-media thickness as a marker of the presence of severe symptomatic coronary artery disease. Eur Heart J. 15:1994;781-785
4. Crouse J.R. III, Craven T.E., Hagaman A.P., Bond M.G. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation. 92:1995;1141-1147
5. Mannami T., Baba S., Ogata J. Strong and significant relationships between aggregation of major coronary risk factors and the acceleration of carotid atherosclerosis in the general population of a Japanese city: the Suita Study. Arch Intern Med. 160:2000;2297-2303
6. Hunt K.J., Pankow J.S., Offenbacher S., et al. B-mode ultrasound-detected carotid artery lesions with and without acoustic shadowing and their association with markers of inflammation and endothelial activation: the atherosclerosis risk in communities study. Atherosclerosis. 162:2002;145-155
7. Wu K.K., Folsom A.R., Heiss G., et al. Association of coagulation factors and inhibitors with carotid artery atherosclerosis; early results of the athrosclerosis risk in communities (ARIC) study. Ann Epidemiol. 2:1992;471-480
8. Folsom A.R., Wu K.K., Shahar E., Davis C.E. For the athrosclerosis risk in communities (ARIC) study investigators. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb. 13:1993;1829-1836
9. Salomaa V., Stinson V., Kark J.D., et al. Association of fibrinolytic parameters with early atherosclerosis. The ARIC study. Circulation. 91:1995;284-290
10. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 332:1995;635-641
11. Kumari M., Marmot M., Brunner E. Social determinants of von Willebrand factor: the Whitehall II study. Arterioscler Thromb Vasc Biol. 20:2000;1842-1847
12. Bajaj M.S., Birktoft J.J., Steer S.A., Bajaj S.P. Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 86:2001;959-972
13. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: basic and clinical aspects. Arterioscler Thromb Vasc Biol. 22:2002;539-648
14. Morange P.E., Renucci J.F., Charles M.A., et al. Plasma levels of free and total TFPI, relationship with cardiovascular risk factors and endothelial cell markers. Thromb Haemost. 85:2001;999-1003
15. Kokawa T., Enjyoji K., Kumeda K., et al. Measurement of the free form of TFPI antigen in hyperlipidemia: relationship between free and endothelial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol. 16:1996;802-808
16. Mannami T., Konishi M., Baba S., Nishi N., Terao A. Prevalence of asymptomatic carotid atherosclerotic lesions detected by high-resolution ultrasonography and its relation to cardiovascular risk factors in the general population of a Japanese city: The Suita Study. Stroke. 28:1997;518-525
17. Abumiya T., Enjyoji K., Kokawa T., Kamikubo Y., Kato H. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form of TFPI but not liporotein-associated forms in plasma. J Biochem. 118:1995;178-182
18. Caplice N.M., Mueske C.S., Kleppe L.S., Simari R.D. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation. 98:1998;1051-1057
19. Kaikita K., Takeya M., Ogawa H., et al. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol. 188:1999;180-188
20. Crawley J., Lupu F., Westmuckett A.D., et al. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol. 20:2000;1362-1373
21. Kamikura Y., Wada H., Yamada A., et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol. 55:1997;183-187
22. Soejima H., Ogawa H., Yasue H., et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation. 99:1999;2908-2913
23. Sakkinen P.A., Cushman M., Psaty B.M., et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost. 80:1998;134-139
24. Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med. 342:2000;1792-1801
25. Folsom A.R. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost. 86:2001;366-373
26. Eitzman D.T., Westrick R.J., Xu Z., Tyson J., Ginsburg D. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood. 96:2000;4212-4215
27. Hasenstab D., Lea H., Clowes A.W. Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. Arterioscler Thromb Vasc Biol. 20:2000;853-859
28. Eren M., Painter C.A., Atkinson J.B., Declerck P.J., Vaughan D.E. Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1. Circulation. 106:2002;491-496
29. Tomiyama H., Kimura Y., Mitsuhashi H., et al. Relationship between endothelial function and fibrinolysis in early hypertension. Hypertension. 31:1998;321-327
30. Kaikita K., Fogo A.B., Ma L., et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation. 104:2001;839-844